MEDPAL AI is trading 5.51% down now at £6.69 after a sharp reversal following its recent rally.
- The main company event for September 9, 2026 was the admission of 1,075,872 new shares related to the eMARx acquisition and management awards, increasing issued shares to 779,118,302.
- The announcement does not directly attribute any price movement to the issuance.
- Broader healthcare weakness may have added pressure, but no definitive catalyst was identified.